EHang Reports Third Quarter 2024 Unaudited Financial Results
Record-High Quarterly Revenues, Up 347.8% YoY Achieved Quarterly Adjusted Operating Income2 (non-GAAP) and the Second Consecutive Quarter of Adjusted Net […]
Himax Drives Innovations in Automotive Display Technology with Mass Production of Third-Gen LCD TDDI and High-End OLED Touch IC
TAINAN, Taiwan, Nov. 18, 2024 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (“Himax” or “Company”) (Nasdaq: HIMX), an industry leader in […]
Niu Technologies Announces Unaudited Third Quarter 2024 Financial Results
— Third Quarter Revenues of RMB 1,023.9 million, an increase of 10.5% year-over-year — Third Quarter Net Loss of RMB […]
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive […]
Erik Maris Joins Perella Weinberg
NEW YORK and PARIS, Nov. 18, 2024 (GLOBE NEWSWIRE) — Perella Weinberg Partners (Nasdaq: PWP), a leading global independent advisory […]
LexinFintech Holdings Ltd. to Report Third Quarter 2024 Unaudited Financial Results on November 25, 2024
SHENZHEN, China, Nov. 18, 2024 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading credit technology-empowered […]
REVISED – Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the […]
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted […]
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time […]
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data […]
